New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩82.6b market cap, or US$52.9m). 공시 • Feb 11
Pharos iBio Co., Ltd., Annual General Meeting, Mar 26, 2026 Pharos iBio Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 415, heungan-daero, dongan-gu, gyeonggi-do, anyang South Korea 공시 • Dec 04
Pharos iBio Co., Ltd. announced that it expects to receive KRW 19 billion in funding from Korea Investment Partners Co. Ltd. Pharos iBio Co., Ltd. announced a private placement of Bearer Interest Unguaranteed Unsecured Private Convertible Bonds to raise gross proceeds of KRW 19,000,000,000 on December 3, 2025. The Bonds are 100% convertible into Common Shares of the company at a conversion value of KRW 8,935 into 2,126,468 Common Shares of the company. The Conversion billing period starts December 19, 2026 through November 19, 2030. The transaction includes participation from returning investor Korea Investment & Securities Co., Ltd. for KRW 1,000,000,000, DSC Home Run Fund No. 2 for KRW 5,000,000,000, 2024 IBK Innovation-AJU Good Venture Fund 3.0 for KRW 5,000,000,000, Company K AI Future Tech Fund for KRW 5,000,000,000 and Korea Investment Core Competency Leverage Fund II for KRW 3,000,000,000. The Bonds carry a Maturity Interest Rate of 3% and the maturity date of the Bonds is December 19, 2030. New Risk • Nov 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩9.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩9.4b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₩91.5b market cap, or US$62.3m). New Risk • Nov 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₩70.9b market cap, or US$49.0m). New Risk • Mar 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₩87.3b market cap, or US$59.6m). 공시 • Feb 11
Pharos iBio Co., Ltd., Annual General Meeting, Mar 25, 2025 Pharos iBio Co., Ltd., Annual General Meeting, Mar 25, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 415, heungan-daero, dongan-gu, gyeonggi-do, anyang South Korea New Risk • Jun 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.2b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₩137.2b market cap, or US$99.1m). New Risk • Nov 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). New Risk • Oct 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩133.1b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (₩300m revenue, or US$222k). Minor Risk Market cap is less than US$100m (₩133.1b market cap, or US$98.4m).